4 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow TAS-303: new trials by email Literature Review of TAS-303 trials Research Report on TAS-303
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects TAS-303, [14C]TAS-303 - Healthy Male Subjects | Phase 1 | Completed | Taiho Pharmaceutical Co., Ltd. | 6 | 2022-09-07 | 2023-08-07 |
| A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence TAS-303 18 mg/day, Placebo - Stress Urinary Incontinence | Phase 2 | Completed | Taiho Pharmaceutical Co., Ltd. | 231 | 2020-09-04 | 2022-02-10 |
| Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence TAS-303, Placebo - Stress Urinary Incontinence | Phase 2 | Completed | Taiho Pharmaceutical Co., Ltd. | 337 | 2016-10-20 | 2024-09-26 |
| A Study of TAS-303 in Female Patients With Stress Urinary Incontinence TAS-303 18mg single-dose, Placebo 18mg single-dose, TAS-303 9mg single-dose - Stress Urinary Incontinence | Phase 1 | Completed | Taiho Pharmaceutical Co., Ltd. | 16 | 2015-10-01 | 2016-08-10 |
Lower Urinary Tract Symptoms (3) · Urinary Incontinence (3) · Urinary Incontinence, Stress (3)
Taiho Pharmaceutical Co., Ltd. (4)
Japan (4)